Please ensure Javascript is enabled for purposes of website accessibility

Stratasys to Leverage 3D Printing Prowess, Assist in COVID-19 Testing

By Scott Levine - Apr 23, 2020 at 5:04PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

As officials emphasize the need for testing before reopening the company, the question of adequate supplies remains a pressing issue.

Pivoting from the production of personal protective equipment, Stratasys (SSYS -0.32%) announced today that it's focusing on another critical aspect of the COVID-19 outbreak: testing. To help alleviate supply shortages, Stratasys announced that it is partnering with Origin, which is also focused on additive manufacturing, to help deliver nasopharyngeal (NP) swabs to healthcare workers and medical centers across the United States. According to the agreement, Stratasys will market and promote Origin's 3D-printed NP swabs as Origin strives to ramp up production of the swabs to 1.3 million per week.

Eager to meet the demand for NP swabs, Christopher Prucha, CEO of Origin, said that his company has "been impressed by the speed with which Stratasys has been able to provide thousands of shields to healthcare systems across the country and believe they are the right partner for helping get millions of swabs where they are most needed."

A woman works with a 3D printer.

Image source: Getty Images.

Earlier this month, Stratasys helped to organize a coalition of more than 150 companies and universities to help produce disposable face shields for healthcare workers. In total, the coalition has supply agreements for more than 14,000 face shields per week; however, the company recognizes the need to increase production in order to meet demand of more than 40,000 per week.

Based on a clinical with Beth Israel Deaconess Medical Center, a medical center affiliated with Harvard Medical School, Origin's NP swabs were found to have performed extremely well compared to control swabs and two other 3D printed swabs.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Stratasys Ltd. Stock Quote
Stratasys Ltd.
$18.68 (-0.32%) $0.06

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/02/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.